Key Takeaways
- Urea volumes resilient despite shutdowns: Full-year urea production rose to 34.61 lakh MT even with a 36-day Gadepan-III turnaround and a 14-day Gadepan-I boiler outage, reflecting strong underlying plant efficiency.
- Crop protection is the growth engine: The CPC-SN business delivered a 25% revenue CAGR and a ₹72 crore YoY contribution jump in FY25, driven by volume, fresh product introductions, and strategic procurement.
- TAN project on track for FY26 revenue: Statutory approvals are in place, ₹650 crore has been spent, and commercial production is expected by January 2026, with conservative financial planning assuming a ramp-up below the 80-90% utilisation target.
- Trading portfolio set to surge: Management expects the NPK trading book to possibly double or grow 250% in FY26, with almost all of last year's 5.5 lakh MT volume done in the kharif season alone, contingent on a stable cost-plus policy for DAP.
- What to watch next quarter: Whether the 18 new CPC products and biologicals launch on schedule for kharif, the pace of DAP contracting under the cost-plus policy, and any disclosure on the undisclosed growth projects management is evaluating.
Urea Operations & Energy Efficiency
- Production held up through shutdowns: Gadepan-III underwent a planned 36-day annual turnaround and Gadepan-I lost 14 days to a boiler problem, yet quarterly production still exceeded the prior-year period because Gadepan-I and II ran efficiently.
- Full-year volume growth: Urea production reached 34.61 lakh MT vs 33.83 lakh MT last year, with sales of 34.71 lakh MT vs 32.56 lakh MT, absorbing the incremental output without channel stress.
- Energy savings persist: Benefits from the energy efficiency scheme continue to flow in, and management is continuously examining further energy-efficient projects that carry knock-on volume increases beyond the current 34.6 lakh MT average.
- Subsidy receipts remain timely: A large portion of the ₹265 crore outstanding as of 31 March 2025 has already been received, maintaining the working capital rhythm.
- Fixed cost reimbursement unresolved: Discussions with the government are ongoing with many differing points of view, and management will update investors only when there is clarity.
Baijal: "I think I made a mention last time that we are looking at various other options which I am not at liberty to disclose. And those are making steady progress as we speak."
Crop Protection & Agri-Inputs
- Volume-led quarter: Q4 CPC-SN revenue of ₹39 crore (vs ₹15 crore last year) was mostly volume-driven, as the sugarcane-consuming segment faced little price pressure.
- Full-year contribution leap: CPC-SN contribution rose to ₹247 crore from ₹175 crore, on revenue of ₹926 crore vs ₹760 crore, sustaining a 25% CAGR built over three years.
- Margin stability through procurement judgment: Margins have held steady because Chambal procures strategically and tactically in Q1, sitting at competitive price levels that create necessary margin, with 60-70% of the outcome dependent on judgment calls.
- Product freshness as a moat: Through alliances with technical partners, Chambal gets some products in the year of launch rather than waiting 2-3 years, with 64 SKUs split across weedicides, fungicides and herbicides, 70% of the Indian market being generics makes this differentiation material.
- 18 new products and biologicals incoming: New CPC products are being readied for kharif and rabi, a biological fungicide launches in kharif 2025, a biological nematicide in rabi 2025, and hybrid and research-variety seeds will substantially complete the agri-input profile.
- TERI partnership for bio-nano: The UTTAM PRANAAM bio-nano phosphorus liquid fertiliser has launched, with Chambal holding exclusive global commercial rights on jointly owned IP developed over the next five years.
- Demand outlook tied to normal monsoon: With IMD and SkyMet forecasting a normal monsoon and competitor inventory pressures from past years having cleared, robust CPC segment growth is expected.
- Export manufacturing ruled out for now: Management has evaluated export production or formulation opportunities repeatedly, but the math on acquisition cost versus return consistently comes out lower than the current domestic mode, though the possibility is never ruled out if a reasonable asset appears.
Baijal: "Margins are dependent on how you have strategically bought it. It is a kind of position taking sometimes in this business... those things are your judgmental call 60% to 70%, and how good your judgment is makes the difference."
TAN Project & CAPEX
- Timeline and spend: Statutory approvals are in place, ₹650 crore has been spent to date, and commercial production is targeted for January 2026, with revenues expected by the third or fourth quarter of FY26.
- Conservative ramp-up assumption: Management hopes for 80-90% capacity utilisation but has built financial plans on a more conservative base, declining to provide revenue or EBITDA guidance and asking analysts to benchmark with the industry.
- FY26 CAPEX of ₹1,200 crore: Total capital expenditure for the year is pegged at approximately ₹1,200 crore, funded entirely from internal accruals, covering the TAN completion and other projects.
- IMACID phosphoric acid expansion: Capacity is being increased from roughly 5 lakh MT to 7 lakh MT, with availability expected in the 2027 timeframe, securing backward integration as China becomes an unreliable P&K supplier.
- Undisclosed growth projects: Management is evaluating various other options that are making steady progress but declined to disclose details or hazard a guess on ticket size, saying only that they are not small projects.
Baijal: "We all hope for the best. We would expect it to go to at least 80%, 90%. But as far as our financial planning is concerned, we are more conservative."
Fertiliser Trading & P&K Dynamics
- Trading portfolio set for sharp expansion: FY26 NPK volumes are expected to possibly double or grow 250%, with almost the entire 5.5 lakh MT done last year being executed in kharif itself, while MOP may stay flat or slightly subdued and DAP grows subject to government policy continuity.
- DAP imports hinge on cost-plus policy: Chambal has already contracted roughly 130,000 MT including TSP volumes, and if the current cost-plus model continues, management has no hesitation in increasing volumes and expects to surpass last year.
- China supply risk is structural: China has become an off-and-on supplier of P&K fertilisers and urea for three years, possibly diverting phosphoric acid capacity to EV battery manufacturing or for geopolitical reasons, forcing a shift in sourcing to Morocco, Saudi Arabia, Jordan, Russia, or the US.
- Geographical concentration risk in rock: Unlike urea and ammonia markets which are more open, the geographical concentration of rock and raw material for P&K creates monopolistic supply dynamics that require active supplier diversification.
- Policy normalisation as a volume catalyst: Management believes that as the P&K policy starts to open and get rationalised, volumes will spring back, implying current policy uncertainty is suppressing demand.
Baijal: "China, from being a very steady supplier of P&K fertilisers and even urea to some extent has now become an off and on kind of party for the last 3 years."
Segment Profitability & Margins
- Own manufactured fertiliser margin compressed: Segment margin fell from 17% to 3.4%, driven by the policy principle on production beyond reassessed capacity, plus heavy repair and maintenance debits from the Gadepan-III annual turnaround and Gadepan-I shutdown with associated startup and shutdown expenses.
- Complex fertiliser segment asset build is tactical: The segment asset increase from ₹825 crore to ₹1,601 crore reflects tactical stock building of purchased inventory, not plant and machinery, and the benefits will flow when sales occur in the kharif season.
- Complex fertiliser profit thin on low Q4 volumes: The ₹9 crore profit on ₹166 crore revenue reflects less than half a lakh MT sold in the quarter, a seasonal trough that reverses in kharif.
- JV profitability improving: JV production increased from 4.35 lakh MT to 5.25 lakh MT and sales from 3.8 lakh MT to 4.35 lakh MT, contributing to the consolidated picture.
- Management declined margin guidance: When asked for a ballpark margin number, management explicitly declined to hazard a guess, pointing instead to the judgment-driven nature of procurement margins.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| TAN commercial production | Production to begin; revenues expected | January 2026; Q3/Q4 FY26 |
| TAN capacity utilisation | Hope for 80-90%; financial planning more conservative | Post-commissioning ramp-up |
| FY26 CAPEX | Approximately ₹1,200 crore, funded from internal accruals | FY26 |
| CPC new product launches | 18 new products across kharif and rabi; biological fungicide in kharif, nematicide in rabi | Kharif 2025 and Rabi 2025 |
| Hybrid and research seeds launch | Substantially complete agri-input product profile | Kharif 2025 |
| Fertilisers trading portfolio | NPK possibly doubling or growing 250%; almost all of last year's volume in kharif itself | FY26, subject to policy continuity |
| DAP import volumes | Expect to surpass last year's volumes | FY26, subject to cost-plus policy continuing |
| IMACID phosphoric acid capacity | Increase from ~5 lakh MT to 7 lakh MT | Available by 2027 |
| TERI partnership IP | Exclusive global commercial rights on jointly developed products | Next five years |
| CPC-SN margin performance | Propose to repeat steady margin performance | FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Standalone revenue | ₹2,449 crore |
| PAT | ₹100 crore, growth of about 16% YoY |
| Full-year FY25 EBITDA | ₹2,838 crore, growth of about 17% YoY |
| Full-year FY25 PAT | ₹1,657 crore, growth of 24% YoY |
| Full-year urea production | 34.61 lakh metric tons, vs 33.83 lakh metric tons last year |
| Full-year urea sales | 34.71 lakh metric tons, vs 32.56 lakh metric tons last year |
| Urea capacity utilization | 99% |
| Q4 gas price | $15.55/mmbtu on NCV basis |
| Subsidy outstanding | ₹265 crore as of March 31, 2025 |
| CPC-SN full-year revenue | ₹926 crore, vs ₹760 crore last year |
| CPC-SN full-year contribution | ₹247 crore, vs ₹175 crore last year |
| CPC-SN Q4 revenue | ₹39 crore, vs ₹15 crore last year |
| CPC-SN Q4 contribution | ₹15 crore, higher by about ₹7 crore YoY |
| CPC-SN CAGR | 25% compounded |
| CPC product portfolio | 64 products of distinct chemistries |
| New CPC products introduced in FY25 | 12 products, primarily weedicides |
| Biologicals share of CPC-SN revenue | 8% of total CPC-SN revenue in FY25 |
| Fertiliser trading portfolio FY25 volume | About 5.5 lakh tons, split between MOP, DAP, TSP and NPKs |
| DAP contracted for upcoming season | Almost 1,30,000 tons, including TSP volumes |
| Ammonia sold in FY25 | Over 1.03 lakh tonnes |
| TAN plant spend till date | About ₹650 crore |
| TAN plant capacity | 2,40,000 tons |
| FY26 total CAPEX guidance | About ₹1,200 crore (per an analyst's math, ₹1,250 crore stated for April–March 26) |
| FY26 TAN project CAPEX | Almost ₹900 crore |
| FY26 routine CAPEX | About ₹300 crore |
| IMACID JV FY25 production | About 5.25 lakh tons, vs about 4.35 lakh tons last year |
| IMACID JV FY25 sales | About 4.35 lakh tons, vs about 3.8 lakh tons last year |
| IMACID phosphoric acid capacity expansion | From about 5 lakh metric tons to 7 lakh metric tons, expected by 2027 |
| Net debt | Negative (net cash) as of March 31, 2025 |